drugset
drugset / Trial / NCT05159700

A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

NCT05159700 ↗

Phase 1 Active not recruiting 39 enrolled Zhuhai Yufan Biotechnologies Co., Ltd
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase I, multicenter, open-label, 3+3 dose escalation study to determine the safety and preliminary efficacy of PRJ1-3024 in subjects with relapsed/refractory solid tumors.

Timeline

Start
2022-03-31
Primary completion
2024-07-17
Completion
2026-06-29

Drugs

EvaluationDrugModalityDoseRoute
Subject PRJ1-3024 Small molecule 80 mg Oral

Indications

neoplasm